Biotech Values

[tony111]

How is it disingenuous? I think everyone knows that comparing lambda data to historical alpha data doesn't mean much. However, such a dramatic difference in tolerability is still encouraging and is in line with MOA of lambda. If you expect the safety profile to be a lot worse when combined with ribavirin, will the efficacy also be far more superior compared to the alpha combo based on the CC slide?